Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Formoterol dry-powder inhalation - Novartis/SkyePharma

Drug Profile

Formoterol dry-powder inhalation - Novartis/SkyePharma

Alternative Names: Foradil Certihaler; Foradil MDDPI; Foradil MDPI; Foradil SkyeHaler; Formoterol Certihaler; Formoterol fumarate dry-powder inhalation - Novartis/SkyePharma

Latest Information Update: 22 Jul 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SkyePharma PLC
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Market Withdrawal Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 24 Jul 2013 Biomarkers information updated
  • 17 Jul 2009 SkyePharma terminates its contracts with Novartis & a subcontractor for Formoterol Certihaler
  • 19 Dec 2008 Discontinued - Registered for Asthma in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top